- Home
- CNX vs WGS Comparison
CNX vs WGS Comparison
Compare CNX & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNX | WGS |
|---|---|---|
| Founded | 1860 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.6B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNX | WGS |
|---|---|---|
| Price | $40.36 | $161.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $33.40 | ★ $130.63 |
| AVG Volume (30 Days) | ★ 1.6M | 496.4K |
| Earning Date | 10-30-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.02 | 0.07 |
| Revenue | ★ $1,930,542,000.00 | $402,190,000.00 |
| Revenue This Year | $49.64 | $41.17 |
| Revenue Next Year | $2.63 | $23.53 |
| P/E Ratio | ★ $20.03 | $2,205.22 |
| Revenue Growth | 40.99 | ★ 50.50 |
| 52 Week Low | $27.00 | $55.17 |
| 52 Week High | $40.68 | $170.87 |
Technical Indicators
Market Signals| Indicator | CNX | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 76.40 | 67.46 |
| Support Level | $38.62 | $158.15 |
| Resistance Level | $39.50 | $170.87 |
| Average True Range (ATR) | 1.00 | 8.87 |
| MACD | 0.20 | 1.42 |
| Stochastic Oscillator | 92.47 | 81.97 |
Price Performance
Historical ComparisonAbout CNX CNX Resources Corporation
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.